Safety and efficacy of venetoclax-azacitidine combined with low-dose Idarubicin and cytarabine regimens for the treatment of newly diagnosed acute myeloid leukemia patients compared to the standard chemotherapy: a propensity score-matched real-world single-center experience
Abstract Despite advances in treatment, long -term survival in patients with acute myeloid leukemia (AML) remains unsatisfactory. Standard induction chemotherapy achieves complete remission (CR) rates of 60%-80% in newly diagnosed AML patients; however, relapse and chemoresistance persist as major c...
Збережено в:
| Автори: | , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Springer
2025-12-01
|
| Серія: | Annals of Hematology |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1007/s00277-025-06653-y |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|